Log in

NASDAQ:ANCNANCHIANO THERAP/S Stock Price, Forecast & News

$0.98
+0.01 (+1.33 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.91
Now: $0.98
$1.01
50-Day Range
$0.78
MA: $1.27
$1.68
52-Week Range
$0.51
Now: $0.98
$3.33
Volume129,282 shs
Average Volume59,140 shs
Market Capitalization$7.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANCN
CUSIPN/A
CIKN/A
Phone857-259-4622

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.01 per share

Profitability

Net Income$-27,120,000.00

Miscellaneous

Employees19
Market Cap$7.27 million
Next Earnings DateN/A
OptionableNot Optionable
$0.98
+0.01 (+1.33 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions

How has ANCHIANO THERAP/S's stock been impacted by COVID-19 (Coronavirus)?

ANCHIANO THERAP/S's stock was trading at $0.8191 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANCN stock has increased by 19.7% and is now trading at $0.9801.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ANCHIANO THERAP/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ANCHIANO THERAP/S
.

How were ANCHIANO THERAP/S's earnings last quarter?

ANCHIANO THERAP/S (NASDAQ:ANCN) posted its earnings results on Thursday, May, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.14.
View ANCHIANO THERAP/S's earnings history
.

What price target have analysts set for ANCN?

3 brokers have issued twelve-month target prices for ANCHIANO THERAP/S's shares. Their forecasts range from $16.00 to $16.00. On average, they expect ANCHIANO THERAP/S's share price to reach $16.00 in the next year. This suggests a possible upside of 1,532.5% from the stock's current price.
View analysts' price targets for ANCHIANO THERAP/S
.

Has ANCHIANO THERAP/S been receiving favorable news coverage?

News headlines about ANCN stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about ANCHIANO THERAP/S
.

Who are some of ANCHIANO THERAP/S's key competitors?

What other stocks do shareholders of ANCHIANO THERAP/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN), Bank of Nova Scotia (BNS), British American Tobacco (BTI) and Carnival (CCL).

Who are ANCHIANO THERAP/S's key executives?

ANCHIANO THERAP/S's management team includes the following people:
  • Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)
  • Mr. Jonathan Burgin, CFO & COO (Age 58)
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)
  • Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41)

When did ANCHIANO THERAP/S IPO?

(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is ANCHIANO THERAP/S's stock symbol?

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

How do I buy shares of ANCHIANO THERAP/S?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANCHIANO THERAP/S's stock price today?

One share of ANCN stock can currently be purchased for approximately $0.98.

How big of a company is ANCHIANO THERAP/S?

ANCHIANO THERAP/S has a market capitalization of $7.27 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.

What is ANCHIANO THERAP/S's official website?

The official website for ANCHIANO THERAP/S is www.anchiano.com.

How can I contact ANCHIANO THERAP/S?

ANCHIANO THERAP/S's mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.